Alnylam Pharma (ALNY) Tops Q4 EPS by 49c; offers guidance
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $239.56 -2.42%
Revenue Growth %: +15.3%
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +15.3%
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($0.77), $0.49 better than the analyst estimate of ($1.26). Revenue for the quarter came in at $346.29 million versus the consensus estimate of $436.08 million.
GUIDANCE:
Alnylam Pharma sees FY2024 revenue of $1400-1500 million, versus the consensus of $1770 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Barclays says AI trade is maturing, favors greater diversification
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
